Park et al. demonstrated that AKT1/3 activation induces GLUT5 expression via downregulation of miR-125b-5p; elevated GLUT5 expression subsequently promotes CRC cell migration and chemotherapy resistance, whereas GLUT5 inhibition restores chemotherapy sensitivity 136. The gene discussed is SLC2A5; the disease is colorectal carcinoma.